Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>Resources>Application Notes>This Application Note
  Application Notes
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Scroll Up
Scroll Down

Performing ADCC Reporter Bioassay with an Environmentally Controlled Microplate Reader
Bookmark and Share

Tecan Group Ltd.

Bioassays designed to measure antibody-dependent cell-mediated cytotoxicity (ADCC) are particularly useful when looking to understand and characterize mechanism of action, and to quantify biologic potency and stability of target compounds during discovery and development.

However, the labor and skill required to isolate primary natural killer cells for ADCC or to maintain alternative cell lines in culture with any level of reproducibility remains problematic, with high costs in consumable reagents and in purchasing and maintaining basic equipment.

Promega has developed reporter bioassays that use activation of gene transcription through NFAT (nuclear factor of activated T-cells) as an earlier measure of ADCC. The bioassays use frozen, thaw-and-use effector and target cells and eliminates the need for cell culture maintenance. The use of frozen cells also decreases assay variability. 

The ADCC Reporter Bioassay requires six-hour incubation with cells and antibody for optimal NFAT activation and luciferase expression to occur.The Tecan Infinite® 200 PRO, equipped with an external module that enables simultaneous adjustment of CO2 and O2, provides an alternative method enabling scientists without access to a cell culture facility to easily perform the bioluminescent reporter bioassay.

Further Information


Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos